GlassScriptPhysician profile
Ronald H Falcon
NPI 1801853965
$3,046.54
in general payments reported to CMS, 2019-2025
25 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $163 · 2021: $106 · 2022: $545 · 2023: $428 · 2024: $339 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $507.95 | 2019-2023 | |
| Lilly USA, LLC | $353.20 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Genzyme Corporation | $233.38 | 2019-2024 | |
| Biofrontera INC. | $215.68 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Sandoz INC. | $128.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $118.20 | 2022-2024 | Sotyktu |
| Amgen INC. | $117.96 | 2019-2024 | Otezla |
| Mayne Pharma Commercial LLC | $90.10 | 2019-2020 | |
| Allergan, INC. | $72.52 | 2019-2022 | |
| Galderma Laboratories, L.P. | $63.61 | 2019-2022 | |
| Smith+Nephew, INC. | $63.25 | 2019-2023 | Collagenase Santyl, Regranex |
| Incyte Corporation | $55.00 | 2022-2024 | Opzelura |
| Glenmark Therapeutics INC. | $51.00 | 2019 | |
| Pfizer INC. | $50.77 | 2019-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $42.32 | 2023 | Dupixent |
| Taro Pharmaceuticals USA, INC. | $39.18 | 2019 | |
| Ucb, INC. | $26.94 | 2025 | Bimzelx |
| Almirall LLC | $23.70 | 2019 | |
| Sun Pharmaceutical Industries INC. | $23.58 | 2020 | |
| Aclaris Therapeutics, INC. | $22.35 | 2019 | |
| Dermira, INC. | $21.23 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.96 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.28 | 2019 | |
| Dermavant Sciences, INC. | $14.14 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Falcon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.